香港地区药物安全网对大病医疗保障的启示
发布时间：2019-07-16 07:44
【摘要】：补偿患者高值药品费用是大病医疗保障的重要途径。我国香港地区建立了药物安全网,在提高高值药品可及性、减轻患者疾病负担等方面取得了显著成效。本文系统梳理了香港地区药物安全网的历史沿革、药品纳入流程、药品及患者申请条件、发展现状以及特点。指出我国内地虽已逐步通过药品谈判建立保障大病的高值药品目录,但机制尚不成熟。应借鉴香港地区药物安全网,建立高值药品目录的准入与退出机制,实现高值药品目录与基本医疗保险目录、新农合基本用药目录的衔接。同时建立多渠道、社会化的筹资机制,扩大高值药品保障范围。最后坚持买赠结合的谈判原则,改革单一的定比例补偿方式,以进一步加强大病医疗保障。
[Abstract]:It is an important way to compensate the high value drug cost of patients for medical security for serious diseases. A drug safety net has been established in Hong Kong, China, which has achieved remarkable results in improving the accessibility of high-value drugs and reducing the burden of diseases on patients. This paper systematically combs the historical evolution, drug inclusion process, drug and patient application conditions, development status and characteristics of drug safety network in Hong Kong. It is pointed out that although the mainland of China has gradually established a catalogue of high value drugs to guarantee serious diseases through drug negotiation, the mechanism is not yet mature. We should draw lessons from the drug safety net in Hong Kong, establish the access and withdrawal mechanism of the catalogue of high value drugs, and realize the connection between the catalogue of high value drugs and the catalogue of basic medical insurance and the catalogue of basic drugs used by NCMS. At the same time, we will establish a multi-channel and socialized financing mechanism to expand the scope of high-value drug security. Finally, we should adhere to the negotiation principle of the combination of purchase and gift, and reform the single proportional compensation method in order to further strengthen the medical security of serious illness.
【作者单位】： 中国药科大学国际医药商学院;
【基金】：国家自然科学基金面上项目(71273278) 2014年度高校“青蓝工程”项目
【分类号】：F842.684;R197.1
本文编号：2514934
[Abstract]:It is an important way to compensate the high value drug cost of patients for medical security for serious diseases. A drug safety net has been established in Hong Kong, China, which has achieved remarkable results in improving the accessibility of high-value drugs and reducing the burden of diseases on patients. This paper systematically combs the historical evolution, drug inclusion process, drug and patient application conditions, development status and characteristics of drug safety network in Hong Kong. It is pointed out that although the mainland of China has gradually established a catalogue of high value drugs to guarantee serious diseases through drug negotiation, the mechanism is not yet mature. We should draw lessons from the drug safety net in Hong Kong, establish the access and withdrawal mechanism of the catalogue of high value drugs, and realize the connection between the catalogue of high value drugs and the catalogue of basic medical insurance and the catalogue of basic drugs used by NCMS. At the same time, we will establish a multi-channel and socialized financing mechanism to expand the scope of high-value drug security. Finally, we should adhere to the negotiation principle of the combination of purchase and gift, and reform the single proportional compensation method in order to further strengthen the medical security of serious illness.
【作者单位】： 中国药科大学国际医药商学院;
【基金】：国家自然科学基金面上项目(71273278) 2014年度高校“青蓝工程”项目
【分类号】：F842.684;R197.1
【相似文献】
相关期刊论文 前2条
1 张曦;;符合GLP法规的计算机系统管理[J];医学理论与实践;2011年01期
2 ;[J];;年期
相关重要报纸文章 前8条
1 曲俊雅;美国药物安全监督体系遭批评[N];经济参考报;2006年
2 记者 关媛媛;药物毒理试验不用再到外地[N];重庆日报;2009年
3 记者原国锋;国家药物安全评价检测中心挂牌[N];人民日报;2002年
4 王雪飞 余运西;把好用药安全第一关[N];健康报;2005年
5 记者 杨玲玲;中日药品安监合作项目见成效[N];中国医药报;2002年
6 吴志军;国家北京药物安全评价中心通过GLP认证[N];中国医药报;2005年
7 本报记者 李雪墨;四家药研中心获首批GLP试点认证[N];中国高新技术产业导报;2002年
8 本报记者 王勇;“名”正“研”顺出新药[N];医药经济报;2002年
，本文编号：2514934
本文链接：https://www.wllwen.com/jingjilunwen/bxjjlw/2514934.html
